Skip to Content

Kyprolis Side Effects

Generic Name: carfilzomib

Note: This page contains information about the side effects of carfilzomib. Some of the dosage forms included on this document may not apply to the brand name Kyprolis.

For the Consumer

Applies to carfilzomib: intravenous powder for solution

In addition to its needed effects, some unwanted effects may be caused by carfilzomib (the active ingredient contained in Kyprolis). In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking carfilzomib, check with your doctor or nurse immediately:

More common:
  • Agitation
  • black, tarry stools
  • bleeding gums
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blood in the urine or stools
  • blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chest pain
  • coma
  • confusion
  • cough or hoarseness
  • decreased urine output
  • depression
  • difficult or labored breathing
  • difficulty with moving
  • dizziness
  • drowsiness
  • fast or irregular heartbeat
  • headache
  • hostility
  • irregular heartbeat
  • irritability
  • lethargy
  • lower back or side pain
  • muscle spasms (tetany) or twitching
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • pounding in the ears
  • rapid weight gain
  • seizures
  • slow or fast heartbeat
  • stupor
  • tightness in the chest
  • tingling of the hands or feet
  • trembling
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss
Less common:
  • Chills
  • fever
  • muscle pain or cramps
  • painful blisters on the trunk of the body
  • weakness in the arms, hands, legs, or feet
  • Dark-colored urine
  • general feeling of discomfort or illness
  • general feeling of tiredness or weakness
  • light-colored stools
  • stomach pain, continuing
  • thickening of bronchial secretions
  • yellow eyes or skin
Incidence not known:
  • Blindness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fainting
  • joint pain, stiffness, or swelling
  • seizures
  • stomach pain
  • sweating

Minor Side Effects

Some of the side effects that can occur with carfilzomib may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Back pain
  • body aches or pain
  • bone pain
  • constipation
  • diarrhea
  • dry mouth
  • ear congestion
  • flushed, dry skin
  • fruit-like breath odor
  • increased hunger
  • increased thirst
  • increased urination
  • loss of appetite
  • loss of voice
  • metallic taste
  • muscle weakness
  • pain in the arms or legs
  • runny nose
  • sneezing
  • sore throat
  • trouble sleeping
  • weight loss

For Healthcare Professionals

Applies to carfilzomib: intravenous powder for injection


Very common (10% or more): Anemia (46.8%), thrombocytopenia (36.3%), lymphopenia (24%), neutropenia (20.7%), leukopenia (13.5%)
Postmarketing reports: Thrombocytopenic purpura/hemolytic uremic syndrome[Ref]


Very common (10% or more): Hypertension (14.3%)
Common (1% to 10%): Cardiac failure events (e.g., pulmonary edema, decreased ejection fraction)
Frequency not reported: Cardiac arrest, congestive heart failure with decreased left ventricular function or myocardial ischemia[Ref]


Very common (10% or more): Increased aspartate aminotransferase (12.5%)
Uncommon (0.1% to 1%): Hepatic failure
Frequency not reported: Elevated serum transaminases, elevated bilirubin

Nervous system

Very common (10% or more): Headache (27.6%), peripheral neuropathy (14%), dizziness (12.5%), hypoesthesia (12.2%)
Postmarketing reports: Posterior reversible encephalopathy syndrome[Ref]


Very common (10% or more): Fatigue (55.5%), pyrexia (30.4%), peripheral edema (24%), chills (16%), arthralgia (15.8%), muscle spasms (14.4%), asthenia (13.9%), pain (12%)
Frequency not reported: Infusion reactions


Very common (10% or more): Dyspnea (34.6%), upper respiratory tract infection (28.3%), cough (26%), pneumonia (12.7%)
Common (1% to 10%): Pulmonary hypertension[Ref]


Uncommon (0.1% to 1%): Tumor lysis syndrome


Very common (10% or more): Nausea (44.9%), diarrhea (32.7%), vomiting (22.2%), constipation (20.9%)[Ref]


Very common (10% or more): Increased blood creatinine (24.1%)
Common (1% to 10%): Renal failure[Ref]


Very common (10% or more): Hypokalemia (13.7%), hypomagnesemia (13.5%), anorexia (12%), hyperglycemia (11.8%), hypercalcemia (11%), hypophosphatemia (10.5%), hyponatremia (10.3%)
Postmarketing reports: Dehydration[Ref]


Very common (10% or more): Back pain (20.2%), extremity pain (13.3%), chest wall pain (11.4%)[Ref]


The most common adverse reactions (30% or greater incidence) are fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia.[Ref]


Very common (10% or more): Insomnia (17.9%)


Common (1% to 10%): Herpes zoster reactivation[Ref]


Postmarketing reports: Rash


1. "Product Information. Kyprolis (carfilzomib)." Onyx Pharmaceuticals Inc, South San Francisco, CA.

Not all side effects for Kyprolis may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.